8-K - Tonix Pharmaceuticals Holding Corp. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Tonix Pharmaceuticals announced Phase 1 data for TNX-4800, a Lyme disease prophylactic, and outlined plans for an adaptive Phase 2 field study expected to initiate in the first half of 2027 pending FDA clearance.

Key Takeaways

1Phase 1 data for TNX-4800 demonstrated safety, tolerability, and pharmacokinetics supportive of approximately four months of protection against Lyme disease.

2The company plans a randomized, double-blind, placebo-controlled adaptive Phase 2 field study expected to start in H1 2027, pending FDA clearance.

3The Phase 2 study will evaluate a single 350 mg subcutaneous dose in participants aged 16 to 65 in Lyme-endemic areas, with primary endpoint prevention at four months.

4TNX-4800 is a long-acting human monoclonal antibody targeting OspA, licensed from UMass Chan Medical School in 2025, intended as a single-dose seasonal prophylactic.

5There are currently no FDA-approved vaccines or prophylactics to protect against Lyme disease in the U.S.

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including Exhibits 99.01, 99.02 and 99.03 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Uni

Regulation Fd

8.01

| Other Events. | |---|---| On March 31, 2026, the Company announced program updates on its TNX-4800 product candidate for protection against Lyme disease, incl

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| | (d) | | Exhibit No. | | Description. | |---|---|---|---|---| | | | 99.01 | | Press Release of the Company, Ma

Exhibits Only

Source Document

Exhibits (4)

8-K

CURRENT REPORT

99.01

PRESS RELEASE

99.02

CORPORATE PRESENTATION, MARCH 31, 2026

99.03

PRESENTATION, MARCH 30, 2026